These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 33555197)

  • 1. Tumor-Associated Macrophages Promote Oxaliplatin Resistance
    Lan H; Liu Y; Liu J; Wang X; Guan Z; Du J; Jin K
    Mol Pharm; 2021 Mar; 18(3):1026-1037. PubMed ID: 33555197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. METTL3 facilitates tumor progression via an m
    Li T; Hu PS; Zuo Z; Lin JF; Li X; Wu QN; Chen ZH; Zeng ZL; Wang F; Zheng J; Chen D; Li B; Kang TB; Xie D; Lin D; Ju HQ; Xu RH
    Mol Cancer; 2019 Jun; 18(1):112. PubMed ID: 31230592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TGM2, HMGA2, FXYD3, and LGALS4 genes as biomarkers in acquired oxaliplatin resistance of human colorectal cancer: A systems biology approach.
    Cheraghi-Shavi T; Jalal R; Minuchehr Z
    PLoS One; 2023; 18(8):e0289535. PubMed ID: 37535601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Annexin A3 depletion overcomes resistance to oxaliplatin in colorectal cancer via the MAPK signaling pathway.
    Xu R; Yin J; Zhang Y; Zhang S
    J Cell Biochem; 2019 Sep; 120(9):14585-14593. PubMed ID: 30998268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CPT2 downregulation triggers stemness and oxaliplatin resistance in colorectal cancer via activating the ROS/Wnt/β-catenin-induced glycolytic metabolism.
    Li H; Chen J; Liu J; Lai Y; Huang S; Zheng L; Fan N
    Exp Cell Res; 2021 Dec; 409(1):112892. PubMed ID: 34688609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNA N
    Chen H; Gao S; Liu W; Wong CC; Wu J; Wu J; Liu D; Gou H; Kang W; Zhai J; Li C; Su H; Wang S; Soares F; Han J; He HH; Yu J
    Gastroenterology; 2021 Mar; 160(4):1284-1300.e16. PubMed ID: 33217448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CPEB3 inhibits epithelial-mesenchymal transition by disrupting the crosstalk between colorectal cancer cells and tumor-associated macrophages via IL-6R/STAT3 signaling.
    Zhong Q; Fang Y; Lai Q; Wang S; He C; Li A; Liu S; Yan Q
    J Exp Clin Cancer Res; 2020 Jul; 39(1):132. PubMed ID: 32653013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. METTL3 antagonizes 5‑FU chemotherapy and confers drug resistance in colorectal carcinoma.
    Li M; Xia M; Zhang Z; Tan Y; Li E; Guo Z; Fang M; Zhu Y; Hu Z
    Int J Oncol; 2022 Sep; 61(3):. PubMed ID: 35856434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. m
    Shen C; Xuan B; Yan T; Ma Y; Xu P; Tian X; Zhang X; Cao Y; Ma D; Zhu X; Zhang Y; Fang JY; Chen H; Hong J
    Mol Cancer; 2020 Apr; 19(1):72. PubMed ID: 32245489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA-NEF suppressed oxaliplatin resistance and epithelial-mesenchymal transition in colorectal cancer through epigenetically inactivating MEK/ERK signaling.
    Shi CJ; Xue ZH; Zeng WQ; Deng LQ; Pang FX; Zhang FW; Fu WM; Zhang JF
    Cancer Gene Ther; 2023 Jun; 30(6):855-865. PubMed ID: 36782047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis.
    Wei C; Yang C; Wang S; Shi D; Zhang C; Lin X; Liu Q; Dou R; Xiong B
    Mol Cancer; 2019 Mar; 18(1):64. PubMed ID: 30927925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-193a-5p as a promising therapeutic candidate in colorectal cancer by reducing 5-FU and Oxaliplatin chemoresistance by targeting CXCR4.
    Azar MRMH; Aghazadeh H; Mohammed HN; Sara MRS; Hosseini A; Shomali N; Tamjidifar R; Tarzi S; Mansouri M; Sarand SP; Marofi F; Akbari M; Xu H; Shotorbani SS
    Int Immunopharmacol; 2021 Mar; 92():107355. PubMed ID: 33429333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kaempferol sensitizes cell proliferation inhibition in oxaliplatin-resistant colon cancer cells.
    Park J; Lee GE; An HJ; Lee CJ; Cho ES; Kang HC; Lee JY; Lee HS; Choi JS; Kim DJ; Choi JS; Cho YY
    Arch Pharm Res; 2021 Dec; 44(12):1091-1108. PubMed ID: 34750753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KIF18b-dependent hypomethylation of PARPBP gene promoter enhances oxaliplatin resistance in colorectal cancer.
    Hong B; Lu R; Lou W; Bao Y; Qiao L; Hu Y; Liu K; Chen J; Bao D; Ye M; Fang Z; Gong C; Zhang X
    Exp Cell Res; 2021 Oct; 407(2):112827. PubMed ID: 34508743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. m6A methyltransferase METTL3 maintains colon cancer tumorigenicity by suppressing SOCS2 to promote cell proliferation.
    Xu J; Chen Q; Tian K; Liang R; Chen T; Gong A; Mathy NW; Yu T; Chen X
    Oncol Rep; 2020 Sep; 44(3):973-986. PubMed ID: 32705223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-29b-3p promotes 5-fluorouracil resistance via suppressing TRAF5-mediated necroptosis in human colorectal cancer.
    Wu S; Zhou Y; Liu P; Zhang H; Wang W; Fang Y; Shen X
    Eur J Histochem; 2021 Jun; 65(2):. PubMed ID: 34155879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel exosomal miR-46146 transfer oxaliplatin chemoresistance in colorectal cancer.
    Xu Y; Zhu M
    Clin Transl Oncol; 2020 Jul; 22(7):1105-1116. PubMed ID: 31728833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of ATP-binding cassette subfamily B member 1 by Snail contributes to chemoresistance in colorectal cancer.
    Wang H; Li JM; Wei W; Yang R; Chen D; Ma XD; Jiang GM; Wang BL
    Cancer Sci; 2020 Jan; 111(1):84-97. PubMed ID: 31774615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential of anti-VEGF receptor 2 therapy targeting for M2-tumor-associated macrophages in colorectal cancer.
    Min AKT; Mimura K; Nakajima S; Okayama H; Saito K; Sakamoto W; Fujita S; Endo H; Saito M; Saze Z; Momma T; Ohki S; Kono K
    Cancer Immunol Immunother; 2021 Feb; 70(2):289-298. PubMed ID: 32705303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N
    Zhang K; Zhang T; Yang Y; Tu W; Huang H; Wang Y; Chen Y; Pan K; Chen Z
    Theranostics; 2022; 12(10):4802-4817. PubMed ID: 35832094
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 26.